IBEX 35
11.104,30 +72,00 (+0,65%) Euro Stoxx 50
4.940,61 +33,31 (+0,68%) Dólar/Euro
1,0734 +0,0037 (+0,34%) Petróleo Brent
85,30 +0,06 (+0,07%) Oro
2.337,20 +6,00 (+0,26%) Bitcoin EUR
56.965,89 -2.977,09 (-4,97%)
MorphoSys AG (MOR.SW)
MorphoSys AG
Semmelweisstrasse 7
Planegg 82152
Germany
49 89 899 27-0
https://www.morphosys.com
Sector(es):
Sector:
Empleados a tiempo completo: 464
Descripción
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG.
Gobierno corporativo
El ISS Governance QualityScore de MorphoSys AG, a día 1 de junio de 2024, es 2. Las puntuaciones base son Auditoría: 3; Tablero: 1; Derechos de los accionistas: 1; Compensación: 6.
